Efficacy of switching ICS to salmeterol/fluticasone combination aerosol in patients with adult bronchial asthma

Efficacy of switching ICS to salmeterol/fluticasone combination aerosol in patients with adult bronchial asthma - Efficacy of switching ICS to salmeterol/fluticasone combination aerosol in patients with adult bronchial asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020229

Enrollment

Registered

2015-12-21

Start date

2014-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchial asthma

Interventions

The patients switched from their previous treatment with ICS to SFC, which contained the same amount of ICS. We evaluated the peak expiratory flow (PEF), ACT, and dose counter during a 12-week period.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria were (i) patients who had been using ICS and LABA separately (ii) patients who had been using only ICS and who had an Asthma Control Test (ACT) score < 20.

Exclusion criteria

Exclusion criteria: severe infection, deep fungal infection, active infection, history of drug allergy to SFC, investigator judged as inappropriate for this study

Design outcomes

Primary

Measure	Time frame
the PEF measured in the outpatient department and the ACT during 12 weeks	—

Secondary

Measure	Time frame
the information obtained from a questionnaire given to the patients and medication adherence.	—

Countries

Japan

Contacts

Public ContactKotaro Kajiwara

Matsuyama-Red-Cross-Hospital Department of Respiratory Medicine

k-kajiwara@matsuyama.jrc.or.jp+81899241111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026